NVO Novo Nordisk

Filed: 8 Mar 21, 7:57am



Washington, D.C. 20549









Pursuant to Rule 13a-16 or 15d-16

of the Securities Exchange Act of 1934


March 8, 2021




 (Exact name of Registrant as specified in its charter)



Novo Allé 

DK- 2880, Bagsvaerd 


(Address of principal executive offices)



Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F


Form 20-F [X]          Form 40-F [  ]


Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.


Yes [  ]           No [X]


If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g-32(b):82-________







Novo Nordisk A/S – Share repurchase programme


Bagsværd, Denmark, 8 March 2021 – On 3 February 2021, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 17 billion to be executed during a 12-month period beginning 3 February 2021.


Under the programme initiated 3 February 2021, Novo Nordisk will repurchase B shares for an amount up to DKK 3.0 billion in the period from 3 February 2021 to 3 May 2021.


Since the announcement as of 1 March 2021, the following transactions have been made:



Number of

B shares


purchase price


value, DKK

Accumulated, last announcement1,974,017 885,959,577
1 March 2021100,000446.8344,682,763
2 March 2021115,000450.0351,753,642
3 March 2021125,000442.7855,347,527
4 March 2021125,000436.6054,574,560
5 March 2021115,000430.4349,499,307
Accumulated under the programme2,554,017 1,141,817,376


The details for each transaction made under the share repurchase programme are published on



Page 2 of 2


Transactions related to Novo Nordisk’s incentive programmes have resulted in a net transfer from Novo Nordisk of 1,318 B shares in the period from 1 March 2021 to 5 March 2021. The shares in these transactions were not part of the Safe Harbour repurchase programme.


With the transactions stated above, Novo Nordisk owns a total of 41,456,629 B shares of DKK 0.20 as treasury shares, corresponding to 1.8% of the share capital. The total amount of A and B shares in the company is 2,350,000,000 including treasury shares.


Novo Nordisk expects to repurchase B shares for an amount up to DKK 17 billion during a 12- month period beginning 3 February 2021. As of 5 March 2021, Novo Nordisk has since 3 February 2021 repurchased a total of 2,554,017 B shares at an average share price of DKK 447.07 per B share equal to a transaction value of DKK 1,141,817,376.


Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 45,000 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit, Facebook, Twitter, LinkedIn, YouTube.


Further information 

Anne Margrethe Hauge+45 3079
Michael Bachner (US)+1 609 664
Daniel Muusmann Bohsen+45 3075
Valdemar Borum Svarrer+45 3079
Ann Søndermølle Rendbæk+45 3075
Mark Joseph Root+45 3079
Kristoffer Due Berg (US)+1 609 235





Novo Nordisk A/S

Investor Relations

Novo Allé

2880 Bagsværd



+45 4444 8888


CVR no:

24 25 67 90

  Company announcement No 17 / 2021





Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.


Date: March 8, 2021




Lars Fruergaard Jørgensen

Chief Executive Officer